This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
Temsirolimus 25mg, administered intravenously once a week, was compared with interferon-alpha, which started at a dose of three million units three times per week for the first week, and increased to nine million units three times per week for the second week, and to 18 million units three times per week in the third week, if this dose was tolerated. Both drugs were administered until the disease progressed, symptoms deteriorated, or there were intolerable adverse events. No second-line treatments were considered.
Location/setting
UK/hospital and the community.
Methods

Analytical approach:
The analysis was based on a decision-analytic model, with a 10-year horizon. The authors stated that the perspective of the UK National Health Service (NHS) was taken.
Effectiveness data:
A systematic review identified one published phase III clinical trial. This was a multinational, multi-centre, randomised controlled trial (RCT) of 626 eligible patients, with 209 receiving temsirolimus, 207 receiving interferon-alpha, and 210 receiving both drugs (Hudes, et al. 2007 , see 'Other Publications of Related Interest' below for bibliographic details). The mean age of patients was 59 years, 69% were male, and 81% had clear-cell renal carcinoma. All the clinical data and the data on drug compliance were from this trial. Progression-free survival was the key endpoint and Weibull curves were used to extrapolate the short-term data to the long term.
Monetary benefit and utility valuations:
The utility values were derived from the RCT using the European Quality of life (EQ-5D) questionnaire.
Measure of benefit:
Quality-adjusted life-years (QALYs) were the summary benefit measure and they were discounted at an annual rate of 3.5%.
